Breaking Insights And Company Coverage That Guides Investment Ideas

Exelixis Reports Preliminary Financial Results for Fiscal Year 2024, Offers Financial Guidance for 2025, and Highlights Key Priorities and Milestones Ahead

Exelixis Reports Preliminary Financial Results for Fiscal Year 2024, Offers Financial Guidance for 2025, and Highlights Key Priorities and Milestones Ahead

Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025 – Cabozantinib franchise achieves approximately $1.805 billion in preliminary U.S. net product revenues for fiscal year 2024 – – Fiscal year 2025 net product revenues guidance of $1.95 billion – $2.05 billion – – Presentation […]

Search